Guangzhou Runer Ophthalmic Biotechnology Co. Ltd. has identified complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, asthma, atherosclerosis, Crohn’s disease, glomerular disorders, hemolytic uremic syndrome, neurological disorders and diabetic retinopathy, among others.